Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Healthy Seronegative Adults at High Risk of SARS-CoV-2 Exposure
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 6578
Summary
- Conditions
- Coronavirus Infection
- Covid 19 Disease
- Severe Acute Respiratory Syndrome - CoronaVirus 2 (SARS-CoV-2)
- Type
- Interventional
- Phase
- Phase 2Phase 3
- Design
- Allocation: RandomizedIntervention Model: Sequential AssignmentMasking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)Primary Purpose: Prevention
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04642638
- Collaborators
- Not Provided
- Investigators
- Study Director: Mammen P. Mammen Jr, M.D., FACP, FIDSA Inovio Pharmaceuticals